Tango Therapeutics, Inc. (TNGX) Operating income 2020–2025
Tango Therapeutics, Inc. (TNGX) annual operating income history from SEC filings — each fiscal year as reported.
-$111.3MFY2025 · since FY2020: -$52.2M → -$111.3M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$111.3M | +23.6% |
| FY2024 | -$145.6M | -27.5% |
| FY2023 | -$114.2M | -2.8% |
| FY2022 | -$111.1M | -90.9% |
| FY2021 | -$58.2M | -11.5% |
| FY2020 | -$52.2M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More TNGX financial trends
TNGX RevenueTNGX Net incomeTNGX Net marginTNGX Gross profitTNGX Gross marginTNGX Operating marginTNGX Operating cash flowTNGX Free cash flowTNGX Capital expendituresTNGX Return on equityTNGX Stock buybacksTNGX Dividends paidTNGX Total assetsTNGX Total liabilitiesTNGX Shareholders’ equityTNGX overview →